BBNXNGMHealthcare·Medical Devices#55 in industry

Beta Bionics, Inc.

Reports in 86d· 2026-07-21

-27.8% · 90d

$10.78

-0.39 (-3.49%)

News

(3)

April 2026

Apr 21, 20266 days ago8-KHealthcare

Beta Bionics raises 2026 guidance after robust Q1 2026 revenue

BBNXBeta Bionics, Inc.

# 📰 What This Document Is ✨ This filing is an 8-K report and press release, which means Beta Bionics, Inc. (BBNX) is reporting significant, material news to the public regarding its quarterly performance. Specifically, this document details the company’s financial results for the quarter ended Marc

Read summaryView on SEC EDGAR

Apr 10, 20262 weeks agoARSHealthcare

Beta Bionics (BBNX) Presents iLet Bionic Pancreas Annual Update

BBNXBeta Bionics, Inc.

# 🧾 What This Document Is You're looking at the structure for Beta Bionics' **Annual Report to Security Holders (ARS)**. This isn't the dense, official 10-K filed with the SEC. Think of the ARS as the company's **"greatest hits" album**—a more user-friendly, narrative version of their year designe

Read summaryView on SEC EDGAR

Apr 10, 20262 weeks agoDEF 14AHealthcare

BBNX Proxy Details CEO's $12.19 Million Stock-Heavy Pay

BBNXBeta Bionics, Inc.

# 🧾 What This Document Is This is a **Proxy Statement (DEF 14A)**, an official filing that invites shareholders to vote on key company decisions. It's like an agenda and informational packet for Beta Bionics' upcoming annual meeting. You'll learn who's running the company, how they are paid, and wh

Read summaryView on SEC EDGAR

Key Data

Market Cap$480.4M

Open$11.01

Prev Close$11.17

Day Range$10.73 – $11.40

52W Range$8.80 – $32.71

Volume241,599

P/E (TTM)—

EPS$-1.37

Dividend Yield—

Beta—

Profit Margin-60.27%

Revenue Growth56.60%

Price Target$20.27(+88.1%)

Next Earnings2026-07-21(86d)

Analyst Ratings

Strong Buy11 analysts

Buy 8Hold 3Sell 0

About

Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is headquartered in Irvine, California.

Healthcare · Medical Devices

420 employees

www.betabionics.com